Table 6. Current clinical trials investigating the role of immune checkpoint inhibitor in the treatment of resectable gastric cancer.
| Trial | Phase | Tumour location | Histology | Intervention | Control | Primary endpoint | Secondary endpoints | Status |
|---|---|---|---|---|---|---|---|---|
| KEYNOTE 585 (NCT03221426) | III | - Gastric - GOJ |
Adenoca only | 3x CP or FP or FLOT & Pembrolizumab→Surgery→3x CP or FP or FLOT & Pembrolizumab→11x pembrolizumab | 3x CP or FP or FLOT→Surgery→ 3x CP or FP or FLOT |
OS, EFS, pCR | Toxicity, DFS | Recruiting |
| MATTERHORN (NCT04592913) | III | - Gastric - GOJ |
Adenoca only | 2x FLOT + durvalumab→Surgery→2x FLOT + durvalumab→10x durvalumab | 2x FLOT→Surgery→2x FLOT | EFS | OS, pCR | Recruiting |
| DANTE (NCT03421288) | II | - Gastric - GOJ |
Adenoca only | 4x FLOT + atezolizumab→Surgery→4x FLOT+ atezolizumab→8x atezolizumab | 4x FLOT→Surgery→4x FLOT | DFS, PFS | pCR, R0 resection, OS, Immune cell infiltration rate | Active, not recruiting |
| MONEO (NCT03979131) | II | - Gastric - GOJ |
Adenoca only | 4x FLOT + avelumab→Surgery→4x FLOT + avelumab→Avelumab for 1 year | NA | pCR | OS, DFS, PFS, R0 resection | Recruiting |
| ICONIC (NCT03399071) | II | - Gastric - GOJ - Oesophageal |
Adenoca only | 4x FLOT + avelumab→Surgery→4x FLOT + avelumab→Avelumab for 1 year | NA | pCR | Toxicity, Radiological response rate, PFS, OS | Recruiting |
| PANDA (NCT03448835) | II | - Gastric - GOJ |
Adenoca only | 1x atezolizumab→4x capectabine + oxaliplatin + docetaxel→Surgery | NA | Toxicity | Pathological tumour regression grade | Recruiting |
| IMAGINE (NCT04062656) | II | - Gastric - GOJ |
Adenoca only | 2x nivolumab + relatlimab→If responding: 4x nivolumab + relatliimab→Surgery→Nivolumab for 1 year | 2x nivolumab→If responding: 4x nivolumab→Surgery→Nivolumab for 1 year | pCR | R0 resection, DFS, OS, Toxicity, Perioperative mortality | Recruiting |
| If not responding after 2x nivolumab + relatlimab: 4x nivolumab + FLOT→Surgery→4x nivolumab + FLOT→Nivolumab for 1 year | If not responding after 2x nivolumab: 4x nivolumab + FLOT→Surgery→4x nivolumab + FLOT→Nivolumab for 1 year | |||||||
| ATTRACTION-5 (NCT03006705) | III | Gastric | Adenoca only | Surgery→S-1 for 1 year or CAPOX for 6 months + Nivolumab for 1 year | Surgery→S-1 for 1 year or CAPOX for 6 months + Placebo | RFS | OS, Safety | Recruiting |
GOJ, gastro-oesophageal; EFS, event-free survival; PFS, progression-free survival; RFS, relapse-free survival; OS, overall survival; pCR, complete pathological response; DFS, disease-free survival.